Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Cytokinetics; Amgen and Servier Announce Decision to Move Omecamtiv Mecarbil into Phase 3 (CYTK, Buy, $12.07)

Amgen issued a press release today in which it announced that Servier had decided to exercise its option to commercialize omecamtiv…
Read more…

Cytokinetics: Amgen’s R&D Chief Expresses Great Optimism About Omecamtiv Mecarbil for Treating Congestive Heart Failure (CYTK, Buy, $6.53)

Purpose of This Report

I have written frequently about omecamtiv mecarbil, Cytokinetics’ extremely promising new drug for congestive heart failure…
Read more…

Cytokinetics: Presentation at Heart Failure Society Suggests Myocardial Infarctions Are Not Likely Associated with Omecamtiv Mecarbil (CYTK, $7.61)

Investment Background
Cytokinetics and Amgen first presented data from the ATOMIC HF trial at the European Society of Cardiology Congress (ESC)…
Read more…

Cytokinetics: Clinical Investigators’ Take on ATOMIC-AHF Trial Results (CYTK, $8.01)

Introduction
Cytokinetics issued a press release on the results of the phase II trial of ATOMIC-AHF and then held a conference…
Read more…

Cytokinetics: A Preview of Key Upcoming Clinical Trial Results (CYTK, $10.17)

Introduction
This report is an update on my thinking on Cytokinetics. It should be read in conjunction with earlier reports, especially…
Read more…

Cytokinetics (CYTK, $1.40) Receives a Vote of Confidence from Amgen

Cytokinetics (CYTK) has announced an expansion of the partnering agreement with Amgen (AMGN) for omecamtiv mecarbil, the Company’s lead product…
Read more…